Varespladib methyl is primarily investigated for its potential therapeutic applications in treating inflammatory and cardiovascular conditions. It functions as a potent inhibitor of secretory phospholipase A2 (sPLA2), an enzyme involved in the inflammatory response and the pathogenesis of atherosclerosis. By inhibiting sPLA2, it may reduce inflammation and plaque formation in arteries, making it a candidate for managing acute coronary syndrome and other cardiovascular diseases. Additionally, its anti-inflammatory properties are being explored for use in conditions like sepsis and rheumatoid arthritis. Research is ongoing to evaluate its efficacy and safety in clinical settings.